Skip to main content

Accredited Podcast Episodes

Appendix Cancer Awareness Month With Thomas Abrams, MD
Appendix Cancer Awareness Month With Thomas Abrams, MD
Oncology Data Advisor: Welcome to Oncology Data Advisor. Today, we're having this interview in honor of Appendix Cancer Awareness Month, and I'm joined by our Editor-in-Chief, Dr. Thomas Abrams. Thomas Abrams, MD: Thank you so much for having me, Keira. It's always a pleasure to give a little bit of an overview of a disease I treat and that I see a lot of patients with. Appendiceal cancers are a rare group of malignancies, and we just don't see enough of these patients to build up enough of a cl...
Aligning Treatment Goals and Value-Based Care in Newly Diagnosed Multiple Myeloma With Joseph Kalis, PharmD, BCOP, and Eric Cannon, PharmD, FAMCP
Aligning Treatment Goals and Value-Based Care in Newly Diagnosed Multiple Myeloma With Joseph Kalis, PharmD, BCOP, and Eric Cannon, PharmD, FAMCP
Oncology Data Advisor™ · Aligning Treatment Goals and Value-Based Care in Newly Diagnosed Multiple Myeloma Multiple myeloma is a clonal plasma cell malignancy characterized by several cytogenetic alterations. Treatment planning for individual patients is complicated by factors such as age, frailty, comorbidities, eligibility for autologous stem cell transplantation, and risk stratification (Kumar et al, 2022). Clinicians are challenged with leveraging the best available evidence and...
Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer With Anne Chiang, MD, PhD, and Henry Park, MD, MPH
Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer With Anne Chiang, MD, PhD, and Henry Park, MD, MPH
Oncology Data Advisor™ · Optimizing Treatment Selection, Sequencing, and Tolerability in Small Cell Lung Cancer An estimated 236,740 new cases of lung cancer are reported in the United States annually, and 130,180 people die of the disease. Approximately 14% of cases are classified as small cell lung cancer (SCLC). While SCLC is usually treated with systemic therapy with or without radiation, the 5-year relative survival rate is a dismal 7%, indicating a need for continued research ...